Moleculin Biotech Inc

$0.29
(as of Jun 25, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Moleculin Biotech Inc

Stock Price
$0.29
Ticker Symbol
MBRX
Exchange
NASDAQ

Industry Information for Moleculin Biotech Inc

Sector
Healthcare
Industry
Biotechnology

Company Description for Moleculin Biotech Inc

Website
https://moleculin.com
Country
USA
Full Time Employees
17

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose for the treatment of pathogenic viruses and various cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.

Fundamentals for Moleculin Biotech Inc

Market Capitalization
$4,287,696
EBITDA
$-25,782,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-4.99
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
14,127,500
Percent Owned by Insiders
0.71%
Percent Owned by Institutions
10.47%
52-Week High
52-Week Low

Technical Indicators for Moleculin Biotech Inc

50-Day Moving Average
200-Day Moving Average
RSI
21.56
ATR
0.08

Analyst Ratings for Moleculin Biotech Inc

Strong Buy
0
Buy
2
Hold
1
Sell
0
Strong Sell
0

News About Moleculin Biotech Inc

Jun 21, 2025, 9:25 AM EST
Moleculin Biotech (MBRX) announced the pricing of a public offering consisting of 16,080,000 shares of common stock and Series E warrants to purchase up to 48,240,000 shares of its common stock, at a combined public offering price per share of common stock and accompanying Series E warrants of 37c. See more.
Jun 20, 2025, 9:39 AM EST
* Moleculin Biotech (NASDAQ:MBRX [https://seekingalpha.com/symbol/MBRX]) is offering 16.08M shares or pre-funded warrants and Series E warrants to purchase up to 48.24M shares at $0.37/unit. See more.
Jun 20, 2025, 9:20 AM EST
HOUSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced the pricing of a public offering consisting of 16,080,000 shares of common stock (or pre-funded warrants in lieu thereof) and Series E warrants to purchase up to 48,240,000 shares of its common stock, at a combined public offering price per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying Series E warrants of $0.37. See more.
Jun 18, 2025, 8:13 AM EST
(RTTNews) - Moleculin Biotech, Inc. See more.